PDF) RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The GERCOR NIPICOL phase II study
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
iRECIST: how to do it | Cancer Imaging | Full Text
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
iRECIST: how to do it | Cancer Imaging | Full Text
PDF) Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
EPOS™
soria on Twitter: "#ENA2016 Dr seymour @theNCI @EORTC @aacr on iRECIST goals and limitations https://t.co/2TBUcpcndq" / Twitter
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
How to better understand iRECIST – a new wave in immunotherapeutic
Cancers | Free Full-Text | Lights and Shadows in Immuno-Oncology Drug Development
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
How to better understand iRECIST – a new wave in immunotherapeutic
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
The Radiology Assistant : RECIST 1.1 - and more
How to better understand iRECIST – a new wave in immunotherapeutic
RECIST 1.1 calculator - Radiology calculators
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - ScienceDirect
Statistical Analysis Plan Title: A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combin
